| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/27/2003 | US20030060421 Kits and compositions supporting intracranial perfusions |
| 03/27/2003 | US20030060420 Vegetable oil stabilizers and an uncomplexed phytoestrogen which has been extracted with ethanol, filtered, hydrolyzed with a base and freeze dried; foods |
| 03/27/2003 | US20030060415 Internal entry, such as through an atrium or ventricle, or can be by an external entry through the chest wall; cardiovascular therapeutics |
| 03/27/2003 | US20030060406 Nucleotide sequence that encodes an amino acid sequence by culturing the host cell for expression of polypeptide; agonist or antagonist |
| 03/27/2003 | US20030060400 A modified nucleoside comprising a purine or pyrimidine ring for treating viral infections |
| 03/27/2003 | US20030060397 Method of treating and preventing acute neural lesions with substances that modulate the expression or function of a protein involved in the cell cycle and pharmaceutical preparations containing such substances |
| 03/27/2003 | US20030059944 Method for expression of small antiviral RNA molecules within a cell |
| 03/27/2003 | US20030059943 Inhibition of gene expression in preferential cell; obtain cells, infect with viral particles, recover infected cells, express viral sequences, monitor adjustment in gene expression |
| 03/27/2003 | US20030059922 Sphingosine1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 03/27/2003 | US20030059877 Human cystine knot polypeptide |
| 03/27/2003 | US20030059875 Nucleotide sequences coding polypeptide for use in the treatment prevention and diagnosis of inflammatory blood and cancer disorders |
| 03/27/2003 | US20030059869 Novel G protein-coupled receptor, GAVE3 |
| 03/27/2003 | US20030059865 Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers |
| 03/27/2003 | US20030059859 Vertebrate protein for use in human therapeutic and diagnostics |
| 03/27/2003 | US20030059857 Detecting modulators of g-protein receptor activity; ,obtain sample containing g-protein receptor, incubate with ligand and modulator, monitor bound labeled ligand, compare to control, adjustment in bound ligand indicates modulator |
| 03/27/2003 | US20030059805 Nucleotide sequences coding polyeptide for use in the treatment of growth disorders in humans |
| 03/27/2003 | US20030059796 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis |
| 03/27/2003 | US20030059773 Immunomodulatory formulations and methods for use thereof |
| 03/27/2003 | US20030059498 A protease and an inner salt of a quaternary amine carboxylic acid for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities; improved weight gain; poultry; Eimeria |
| 03/27/2003 | US20030059495 Compositions for appetite control and related methods |
| 03/27/2003 | US20030059484 Cosmetic treatment method for fighting against skin ageing effects |
| 03/27/2003 | US20030059481 Composition for promoting healthy bone structure |
| 03/27/2003 | US20030059479 A cell activating agent comprising a royal jelly and alpha, alpha- trehalose which acts as a stabilizer and preservative at low temperatures; tonic, health food or health supplement; cosmetics |
| 03/27/2003 | US20030059478 Aqueous extract of the plant Soma; a mixture of milk, plant derivatives and a mineral comprising apple cider vinegar, quinine, blackstrap molasses, sulfur and whole milk; anticarcinogenic and -tumor agents |
| 03/27/2003 | US20030059476 A neuroprotective medicament for protecting the central nervous system of a mammal comprising a solution of an amphipathic lipid in oil; protecting central nervous system tissue by replacing cerebrospinal fluid; antiichemic agents |
| 03/27/2003 | US20030059473 Method for preparing colloidal particles in the form of nanocapsules |
| 03/27/2003 | US20030059472 Preparation of submicron sized nanoparticles via dispersion lyophilization |
| 03/27/2003 | US20030059470 Dispersions for the formulation of slightly or poorly soluble agents |
| 03/27/2003 | US20030059469 Protecting the carboxylic acid group of the drug molecule, adding to the drug molecule a chlorinated polyanhydride linker, deprotecting by exposing the linked drug molecules to heat or vacuum, acetylating to produce monomer, polymerizing |
| 03/27/2003 | US20030059465 Stabilized nanoparticle formulations of camptotheca derivatives |
| 03/27/2003 | US20030059462 Dissolving a powder of liposome-forming lipids in an organic solvent to a level close to saturation, adding to the solute obtained a dry, water immiscible carotenoid to obtain a suspension, drying and dehydrating the powder obtained |
| 03/27/2003 | US20030059458 Encapsulated carob fibers having improved product properties, process for production thereof and use thereof |
| 03/27/2003 | US20030059456 Intravaginal drug delivery devices for the administration of an antimicrobial agent |
| 03/27/2003 | US20030059455 A defective recombinant adenovirus including at least one DNA sequence coding for all or an active part of a superoxide; useful for treating and/or preventing Parkinson's disease, Alzheimer's disease, Huntington's disease etc. |
| 03/27/2003 | US20030059454 Optimized dosing for drug coated stents |
| 03/27/2003 | US20030059451 Use of orally administered dehydroepiandrosterone, precursors and derivatives thereof in order to improve the papery aspect of the skin |
| 03/27/2003 | US20030059450 Anti-aging formulation containing a cosmeceutically active base, which is a hydroxide- releasing inorganic or nitrogen containing organic base, the formulation has a pH in the range of about 7.5 to 13.0 |
| 03/27/2003 | US20030059447 Compositions comprising a combination of a free sphingoid base and a ceramide and uses thereof |
| 03/27/2003 | US20030059446 Physically stable sprayable gel composition |
| 03/27/2003 | US20030059440 Composition and method for moisturizing nasal tissue |
| 03/27/2003 | US20030059434 Administering to the subject an effective amount of a chloride channel modulator |
| 03/27/2003 | US20030059433 Screening at least one individual for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor |
| 03/27/2003 | US20030059430 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor |
| 03/27/2003 | US20030059418 Composition for prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10 |
| 03/27/2003 | US20030059417 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2003 | US20030059399 Such as poly(N-(2-hydroxy)ethyl ethylenimine) conjugated with 4-(14'-hydroxy-3'-1'ketotetradecyl)phenylboronic acid for inhibiting the uptake of fat in the gastrointestinal tract; dietetics; side effects reduction |
| 03/27/2003 | US20030059398 Water-soluble stabilized self-assembled polyelectrolytes |
| 03/27/2003 | US20030059397 Solid oral dosage forms of controlled substances having reduced potential for abuse by inhalation, mastication, and injection; for alternative administration of oxycodone |
| 03/27/2003 | US20030059384 Compositions and method for protecting skin from UV induced immunosuppression and skin damage |
| 03/27/2003 | US20030059379 Methods for treating periodontal disease |
| 03/27/2003 | US20030059378 Method of preventing mucositis |
| 03/27/2003 | US20030059375 Method for treating lung cancers |
| 03/27/2003 | US20030059374 Use of metoclopramide |
| 03/27/2003 | US20030059369 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 03/27/2003 | US20030056788 Partial liquid breathing of fluorocarbons |
| 03/27/2003 | CA2492826A1 Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| 03/27/2003 | CA2466243A1 Indolizines as kinase protein inhibitors |
| 03/27/2003 | CA2465978A1 Inhibitors of histone deacetylase |
| 03/27/2003 | CA2461074A1 Methods and compositions of novel triazine compounds |
| 03/27/2003 | CA2461073A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | CA2461072A1 Compounds which inhibit the release of inflammatory cytokines |
| 03/27/2003 | CA2461071A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | CA2461065A1 Transductin-1 and transductin-2 and applications to hereditary deafness |
| 03/27/2003 | CA2460987A1 Pharmaceutical formulations for protecting pharmaceutical compound from acidic environments |
| 03/27/2003 | CA2460947A1 6-o-carbamate-11,12-lacto-ketolide antimicrobials |
| 03/27/2003 | CA2460942A1 Substituted pyrazolyl compounds for the treatment of inflammation |
| 03/27/2003 | CA2460885A1 Composition comprising cysteamine for improving lactation in dairy animals |
| 03/27/2003 | CA2460845A1 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 03/27/2003 | CA2460783A1 Bioprecursors for percutaneous application |
| 03/27/2003 | CA2460719A1 Igf-binding protein-derived peptide or small molecule |
| 03/27/2003 | CA2460713A1 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
| 03/27/2003 | CA2460620A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 03/27/2003 | CA2460578A1 Propanolamine derivative having 1,4-benzodioxane ring |
| 03/27/2003 | CA2460537A1 Compositions for appetite control and related methods |
| 03/27/2003 | CA2460445A1 7-tert-butyl-3-(2-fluorophenyl)-6-(2h-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3-b) pyridazine for the treatment of anxiety and convulsions |
| 03/27/2003 | CA2460442A1 Combination of a pde inhibitor and a leukotriene receptor antagonist |
| 03/27/2003 | CA2460440A1 Salicylic acid salts, processes for preparing them and their use as pharmaceutical compositions |
| 03/27/2003 | CA2460360A1 Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections |
| 03/27/2003 | CA2460358A1 Hydroxyfattysulfonic acid analogs |
| 03/27/2003 | CA2460334A1 Microfabricated nanopore device for sustained release of therapeutic agent |
| 03/27/2003 | CA2460326A1 Method for treating skin disorders |
| 03/27/2003 | CA2460319A1 Lpa receptor agonists and antagonists and methods of use |
| 03/27/2003 | CA2460263A1 Hydroxyeicosenoic acid analogs |
| 03/27/2003 | CA2460244A1 Simplified sarcodictyn derivatives as anti-tumor agents |
| 03/27/2003 | CA2460184A1 Prolactin induced increase in neural stem cell numbers and therapeutical use thereof |
| 03/27/2003 | CA2460151A1 Cytokine receptor |
| 03/27/2003 | CA2460150A1 Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis |
| 03/27/2003 | CA2460149A1 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same |
| 03/27/2003 | CA2460139A1 Method of treating benign prostatic hyperplasia and other benign prostate conditions |
| 03/27/2003 | CA2460126A1 Tricyclic indole derivatives as 5-ht ligands |
| 03/27/2003 | CA2460125A1 Novel compounds and compositions as cathepsin inhibitors |
| 03/27/2003 | CA2460120A1 Compositions and methods for the diagnosis and treatment of tumor |
| 03/27/2003 | CA2460076A1 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| 03/27/2003 | CA2459949A1 Retinoid receptor pan-antagonists for stimulating chondrogenesis |
| 03/27/2003 | CA2459547A1 Method of increasing the presence of glutathione in cells |
| 03/27/2003 | CA2459454A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| 03/27/2003 | CA2458720A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 03/27/2003 | CA2456193A1 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 03/27/2003 | CA2454023A1 Dna-pk inhibitors in the treatment of retroviral mediated diseases |
| 03/27/2003 | CA2452288A1 Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |